Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.46 |
| ▸ | GRM5 | P41594 | 8/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14990423 | 0.89 | NAMPT (0.57) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL12440413 | 0.86 | NAMPT (0.56) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL14790770 | 0.86 | NAMPT (0.56) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL24319593 | 0.85 | TLR7 (0.52) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL31342062 | 0.85 | PDK4 (0.50) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL8054238 | 0.84 | NAMPT (0.54) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL8912847 | 0.83 | NAMPT (0.63) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL17876418 | 0.82 | NAMPT (0.57) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL16492725 | 0.82 | NAMPT (0.54) | NAMPTPDK4WNT3AGRM1GRM5 | |
| SCHEMBL22325023 | 0.81 | NAMPT (0.56) | NAMPTPDK4WNT3AGRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | NAMPT 1924/4885PDK4 2960/4885WNT3A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.